Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20531297
Plaza-Menacho I, et al. (2010) Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29, 4648-57 20531297
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF augment treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF inhibit treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF inhibit treatment-induced increase partial inhibition

S104-p - ER-alpha (human)
Modsite: FPPLNsVsPsPLMLL SwissProt Entrez-Gene
Orthologous residues
ER‑alpha (human): S104‑p, ER‑alpha (mouse): S108‑p, ER‑alpha (rat): S109‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF no change compared to control

S106-p - ER-alpha (human)
Modsite: PLNsVsPsPLMLLHP SwissProt Entrez-Gene
Orthologous residues
ER‑alpha (human): S106‑p, ER‑alpha (mouse): S110‑p, ER‑alpha (rat): S111‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF no change compared to control

S118-p - ER-alpha (human)
Modsite: LHPPPQLsPFLQPHG SwissProt Entrez-Gene
Orthologous residues
ER‑alpha (human): S118‑p, ER‑alpha (mouse): S122‑p, ER‑alpha (rat): S123‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase slight inhibition
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase slight inhibition
SP600125 GDNF no effect upon treatment-induced increase slight inhibiton
rapamycin GDNF inhibit treatment-induced increase

S167-p - ER-alpha (human)
Modsite: GGRERLAsTNDkGSM SwissProt Entrez-Gene
Orthologous residues
ER‑alpha (human): S167‑p, ER‑alpha (mouse): S171‑p, ER‑alpha (rat): S172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase partial inhibition
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF no effect upon treatment-induced increase
rapamycin GDNF inhibit treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF no effect upon treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF no effect upon treatment-induced increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF no effect upon treatment-induced increase slight inhibition
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF inhibit treatment-induced increase slight inhibition

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF no effect upon treatment-induced increase slight inhibition
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF inhibit treatment-induced increase
rapamycin GDNF inhibit treatment-induced increase slight inhibition

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase
GDNF increase
GDNF Ret (human) no effect upon treatment-induced increase siRNA no effect

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase
GDNF increase
GDNF Ret (human) no effect upon treatment-induced increase siRNA no effect

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase slight increase
wortmannin GDNF inhibit treatment-induced increase
SB203580 GDNF no effect upon treatment-induced increase
SP600125 GDNF no effect upon treatment-induced increase
rapamycin GDNF inhibit treatment-induced increase

Y1062-p - Ret (human)
Modsite: TWIENkLyGMsDPNW SwissProt Entrez-Gene
Orthologous residues
Ret (human): Y1062‑p, Ret iso2 (human): Y1062‑p, Ret iso3 (human): Y586‑p, Ret (mouse): Y1063‑p, Ret iso2 (mouse): Y1063‑p, Ret iso4 (mouse): , Ret (rat): Y1063‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  estrogen deprived MCF7 cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase